A study performed by Delker et al. [10] investigated eight prostate cancer patients undergoing combined [177Lu]Lu-PSMA-I&T/[225Ac]Ac-PSMA-I&T therapy. The gene discussed is FOLH1; the disease is prostate carcinoma.